Wall Street brokerages expect Redhill Biopharma Ltd. (NASDAQ:RDHL) to post earnings of ($0.58) per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Redhill Biopharma’s earnings. The highest EPS estimate is ($0.51) and the lowest is ($0.62). Redhill Biopharma reported earnings per share of ($0.60) during the same quarter last year, which would indicate a positive year over year growth rate of 3.3%. The firm is scheduled to report its next earnings report on Tuesday, July 25th.

On average, analysts expect that Redhill Biopharma will report full-year earnings of ($2.23) per share for the current fiscal year, with EPS estimates ranging from ($2.35) to ($2.04). For the next financial year, analysts forecast that the business will report earnings of ($2.23) per share, with EPS estimates ranging from ($2.40) to ($2.05). Zacks’ EPS calculations are an average based on a survey of analysts that cover Redhill Biopharma.

Redhill Biopharma (NASDAQ:RDHL) last posted its quarterly earnings data on Wednesday, May 3rd. The biotechnology company reported ($0.50) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.14.

RDHL has been the subject of a number of research analyst reports. FBR & Co reissued a “buy” rating on shares of Redhill Biopharma in a research report on Wednesday, April 5th. Zacks Investment Research raised shares of Redhill Biopharma from a “hold” rating to a “buy” rating and set a $9.75 price target for the company in a research report on Tuesday, July 4th. Roth Capital set a $26.00 price target on shares of Redhill Biopharma and gave the stock a “buy” rating in a research report on Thursday, May 4th. Finally, HC Wainwright set a $33.00 price target on shares of Redhill Biopharma and gave the stock a “buy” rating in a research report on Thursday, May 4th.

WARNING: “Analysts Expect Redhill Biopharma Ltd. (RDHL) to Post -$0.58 EPS” was first reported by American Banking News and is the property of of American Banking News. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/07/12/analysts-expect-redhill-biopharma-ltd-rdhl-to-post-0-58-eps.html.

A number of institutional investors have recently modified their holdings of the stock. Oppenheimer & Co. Inc. raised its position in shares of Redhill Biopharma by 36.5% in the first quarter. Oppenheimer & Co. Inc. now owns 23,069 shares of the biotechnology company’s stock valued at $221,000 after buying an additional 6,172 shares during the last quarter. Penserra Capital Management LLC raised its position in shares of Redhill Biopharma by 75.0% in the first quarter. Penserra Capital Management LLC now owns 17,843 shares of the biotechnology company’s stock valued at $171,000 after buying an additional 7,647 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Redhill Biopharma during the first quarter valued at $101,000. Family Management Corp acquired a new position in shares of Redhill Biopharma during the first quarter valued at $163,000. Finally, Renaissance Technologies LLC acquired a new position in shares of Redhill Biopharma during the fourth quarter valued at $266,000. 12.31% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Redhill Biopharma (NASDAQ:RDHL) traded up 3.67% during trading on Wednesday, reaching $8.48. 50,083 shares of the company traded hands. Redhill Biopharma has a 12 month low of $8.20 and a 12 month high of $16.54. The firm has a 50-day moving average price of $9.43 and a 200-day moving average price of $9.89. The firm’s market capitalization is $144.22 million.

Redhill Biopharma Company Profile

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.

Get a free copy of the Zacks research report on Redhill Biopharma (RDHL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Redhill Biopharma (NASDAQ:RDHL)

Receive News & Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.